We read with interest the recent CMAJ commentary by Batt and Khan1 about our recent
publications of trials comparing 4 months of rifampin with 9 months of isoniazid in adults2 …

TB less than 2 months after completing a 4-month course of rifampin. The isolate from the
latter individual showed rifampin resistance on genotypic testing but the bacterium was fully …

Background The treatment of latent infection with Mycobacterium tuberculosis is important in
children because of their vulnerability to life-threatening forms of tuberculosis disease. The …

Background: Treatment of latent tuberculosis infection with isoniazid for 9 months is
complicated by poor patient adherence and the need for close follow-up of side effects …

The way that the United States chooses to prevent tuberculosis has always been a subject of
interest to the rest of the world. Its decision in the 1950s not to use Bacille Calmette-Guérin …

Background An important problem limiting treatment of latent tuberculosis infection is the
occurrence of adverse events with isoniazid. We combined populations from phase 2 and …

Background Studies looking at acquired drug resistance (ADR) are diverse with respect to
geographical distribution, HIV co-infection rates, retreatment status and programmatic …

Background: Four months of rifampin treatment for latent tuberculosis infection is safer, has
superior treatment completion rates, and is as effective as 9 months of isoniazid. However …

BACKGROUND. Guidelines for latent tuberculosis infection do not consider drug-resistance
patterns when recommending treatment for immigrant children. OBJECTIVES. The purpose …

As the prevalence of active tuberculosis decreases in the United States, the focus on
treatment of latent tuberculous infection (LTBI) has intensified. However, the standard 6–9 …